A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
At a glance
Conditions
NCT05092347
Where you'd take part
This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Cedars-Sinai Medical Center
Los Angeles, Californiano site contact published
Comprehensive Transplant Center
Chicago, Illinoisno site contact published
Connie Frank Transplant Center at UCSF
San Francisco, Californiano site contact published
John Hopkins Hospital
Baltimore, Marylandno site contact published
Medstar Georgetown Transplant Institute - 2-PHC
Washington D.C., District of Columbiano site contact published
New York University Langone Health
New York, New Yorkno site contact published
Penn Transplant Institute
Philadelphia, Pennsylvaniano site contact published
University of California Irvine
Orange, Californiano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation periodUp to approximately 6 weeks
- Incidence and severity of treatment-emergent adverse events (TEAE)s from the first study drug dose up to the end of the studyUp to 78 weeks
TEAEs include adverse events of special interest (AESI) and serious adverse events (SAEs)